ITGAX and melanoma: Vaccination with CD47KO B16F0 melanoma cells significantly delayed tumor growth in the CD11c+ cell replete, but not in CD11c+ DC-depleted chimeras compared to the controls receiving no tumor cell vaccination (Fig. 7c).